Chiusura precedente | 2.693,50 |
Aperto | 2.661,00 |
Denaro | 2.644,00 x 0 |
Lettera | 2.644,50 x 0 |
Min-Max giorno | 2.636,50 - 2.676,00 |
Intervallo di 52 settimane | 1.856,00 - 3.014,50 |
Volume | |
Media Volume | 3.869.689 |
Capitalizzazione | 3,926T |
Beta (5 anni mensile) | 0,50 |
Rapporto PE (ttm) | 39,74 |
EPS (ttm) | 66,53 |
Prossima data utili | 14 mag 2024 |
Rendimento e dividendo (futuro) | 22,00 (0,82%) |
Data ex dividendo | 28 mar 2024 |
Stima target 1A | 2.973,80 |
U.S. Food and Drug Administration (“FDA”) granted Investigational Device Exemption (“IDE”) approval with conditions for Virtue SAB® coronary in-stent restenosis (“ISR”) U.S. pivotal study (in collaboration with Terumo Corporation (“Terumo”)); study expected to start before the end of 2023BackBeat CNT™ global pivotal study in hypertensive pacemaker patients (in collaboration with Medtronic) on track for initiation in the second half of 2023 NEW HOPE, Pa., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Orchest
Virtue® Sirolimus AngioInfusion Balloon (“SAB”) is the only non-coated angioplasty system providing protected delivery of extended release sirolimus under clinical investigation worldwideVirtue ISR-US pivotal study focused on coronary in-stent restenosis (“ISR”), a difficult-to-treat and serious complication of coronary stenting, currently expected to start before the end of 2023Strategic partnership with Terumo Corporation (“Terumo”) targets coronary ISR and multiple additional vascular indicat